ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)

6 Months Ended

Jun. 30, 2021

Supplemental cash flow information for the six months ended June 30, 2021 and 2020 is as follows:

	2021		2020
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	5,534,279	$	4,192,165
Non-cash Financing and Investing Activities:
Equipment acquired reflected in accounts payable and accrued liabilities	$	1,005,546	$	1,228,000
Right-to-use assets in exchange for lease obligations	$	2,844,875	$	1,723,594